An update on the safety of specific immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 6, 2008, Pages 571-576

  Windom, Hugh H ^a,b   Lockey, Richard F ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

Adverse reactions; Safety; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

ADRENALIN; ALLERGEN; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; BEE VENOM; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GLUCOCORTICOID; GRASS POLLEN EXTRACT; GRASS POLLEN VACCINE; HOUSE DUST ALLERGEN; HYMENOPTERA VENOM; OMALIZUMAB; PLACEBO; SALBUTAMOL;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE RESPIRATORY FAILURE; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; BLISTER; CHEILITIS; CLINICAL TRIAL; DERMATOPHAGOIDES PTERONYSSINUS; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EYE ALLERGY; EYE SWELLING; FAINTNESS; FEVER; FLUSHING; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; IMMUNOTHERAPY; INJECTION SITE SWELLING; INSECT ALLERGY; INTERMETHOD COMPARISON; LIP EDEMA; MOUTH DISCOMFORT; NAUSEA; NOSE ALLERGY; OPTIMAL DRUG DOSE; ORAL PRURITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; RESPIRATORY DISTRESS; REVIEW; RHINOCONJUNCTIVITIS; RHINORRHEA; SIDE EFFECT; THORAX PAIN; THROAT IRRITATION; TONGUE SWELLING; UNSPECIFIED SIDE EFFECT; URTICARIA; WHEEZING;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG TOXICITY; GREAT BRITAIN; HEALTH PLANNING GUIDELINES; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS;

EID: 56749176804     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32831845fb     Document Type: Review

References (45)

1. Lockey RF, Turkeltaub PC, Olive ES, et al. The hymenoptera venom study. III. Safety of venom immunotherapy. J Allergy Clin Immunol 1990; 86:775-780.
2. Stewart GE, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992; 90:567-578.
3. Tabar AI, Garcia BE, Rodriguez A, et al. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993; 48:450-453.
4. Tinkelman DG, Cole WQ, Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995; 95:8-14.
5. Ragusa VF, Massolo A. Nonfatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods. Eur Ann Allergy Clin Immunol 2004; 36:52-55.
6. Moreno C, Cuesta-Herranz J, Fernandez-Tavora L, Alvarez-Cuesta E. Immunotherapy safety: a prospective multicentric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy 2004; 34:527-531.
7. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79:660-677.
8. Amin HS, Liss G, Bernstein DI. Evaluation of near-fatal reactions to allergen-immunotherapy injections. J Allergy Clin Immunol 2006; 117:169-175.
9. Rodriguez F, Boguete M, Ibanez MD, et al. Once daily sublingual immunotherapy without updosing: a new treatment schedule. Int Arch Allergy Immunol 2006; 140:321-326.
10. Kleine-Tebbe J, Kretschmar G, Herold A, et al. Safety and tolerability of escalating doses of microencapsulated grass (Phleum pratense) pollen extract (MGPE) for oral immunotherapy (OIT) in grass pollen subjects. J Allergy Clin Immunol 2008; 121:S128. An abstract comparing the initiation of daily SLIT with a 7-week build-up of doubling dose each week to a maximum of 64000 BAU versus 1 week of treatment of 32 000 BAU without a build-up. Adverse reactions were mild and similar between groups and compared to placebo.
11. Larsen RH, Poulsen LK, Melac M, et al. Safety and tolerability of grass pollen tablets in sublinguql immunotherapy - a phase-1 study. Allergy 2006; 61:1173-1176.
12. Demoly P, Meziane L, LeGall M, et al. Safety and tolerability of house dust mite tablets in sublingual immunotherapy. J Allergy Clin Immunol 2008; 121:S128. An abstract of dust mite SLIT over 10 days in 31 patients comparing initiation schedules. Mild reactions occurred in both groups starting at 300 IR or building up to 500 IR. In the group starting at 500 IR, severe local adverse events were noted.
13. Torres Lima M, Wilson D, Pitkin L, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32:507-514.
14. Alvarez-Cuesta E, Berges-Gimeno P, Mancebo EG, et al. Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study. Allergy 2007; 62:810-817.
15. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338-1345. An optimal dose finding study of 628 adults. Adverse reactions were similar for each of the three doses, affecting 64-69% of patients. No serious systemic events or anaphylaxis occurred during the 6-month study period.
16. de Blay F, Barnig C, Kanny G, et al. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2007; 99:453-461. A multicenter study of 127 seasonal allergic rhinoconjunctivitis patients demonstrating the tendency to local reactions: 49 oral or throat irritation events in the SLIT group versus eight in the placebo group.
17. Cox LS, Linnemann DL, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117:1021-1035.
18. Khinchi MS, Poulsen LK, Carat F, et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004; 59:45-53.
19. Durham SR, Yang W, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-809.
20. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434-440.
21. Dahl R, Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121:512-518. An interim analysis focusing on the second year of treatment from a multicenter study of 351 patients receiving SLIT daily for 22 months. Unlike the first year of SLIT treatment, there was not a predominance of local reactions in the actively treated group.
22. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006; 61:1235.
23. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007; 62:567-568. This was not only the first case report of SLIT-induced anaphylaxis in Europe, it was also unique for the use of a multiallergen extract, containing dust mite and pollens. More studies are necessary to determine if the less common use of multiple allergens will have a poorer safety profile.
24. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008; 63:374. This case report of SLIT-induced anaphylaxis occurred in the third year of treatment and was notable for the potential of self-administration errors. The patient had missed 3 weeks of dosing and then took 6 times her normal dose leading to the near-fatal reaction.
25. Lombardi C, Gargioni S, Cottini M, et al. The safety of sublingual immunotherapy with one or more allergens in adults. Allergy 2008; 63:375-376. A 3-month study addressing the difference in safety of single allergen versus multiple allergen SLIT in 159 patients. In this short study, the adverse events related to SLIT were the same in the two groups.
26. Di Rienzo V, Paguni A, Parmiani S, et al. Postmarketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999; 54:1110-1113.
27. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol 1990; 18:277-284.
28. Valovirta E, Jacobsen L, Ljerring C, et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006; 61:1177-1183.
29. Ibanez MD, Kaiser F, Knecht R, et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 2007; 18:516-522. This was a safety study in grass allergic children taking Grazax for 28 days out of season. Adverse reactions led to two out of 45 patients withdrawing from the study.
30. Pham-Thi N, Scheinmann P, Fadel R, et al. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007; 18:47-57. Unlike studies of rhinitis patients with or without asthma, this study enrolled 115 asthmatic children allergic to dust mites. There was no clinical benefit of 18 months of SLIT therapy.
31. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007; 120:164-170. This study assessed dust mite SLIT for 18 months in 56 children with atopic dermatitis. Adverse events were sparsely reported, but two of the 28 on active SLIT were withdrawn due to generalized itching within an hour of dosing.
32. Roder E, Berger MY, Hop WCJ, et al. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007; 119:892-898. SLIT was offered to 168 grass allergic rhinoconjunctivitis patients in the primary care setting. There was no clinical benefit in the active versus the placebo group.
33. Bufe A, Eberle P, Franke-Beckmann E, et al. Phase III trial with grass allergen tablets for sublingual immunotherapy in children. J Allergy Clin Immunol 2008; 121:S127.
34. Nucera E, Schiavino D, Pollastrini E, et al. Sublingual desensitization in children with congenital malformations and latex allergy. Pediatr Allergy Immunol 2006; 17:606-612.
35. Nettis E, Colanardi MC, Soccio AL, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. British J Dermatol 2007; 156:674-681. Thirty-five patients with latex sensitivity resulting in urticaria or asthma were treated for 1 year with latex SLIT. Three of the 18 in the active group had itching, burning or swelling of the lips during the build-up phase, regressing spontaneously with ongoing dosing.
36. Antico A, Paggani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006; 61:1236-1237.
37. Staden U, Rolinck-Werninghaus C, Brewe F, et al. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy 2007; 62:1261-1269.
38. Buchanan AD, Green TD, Jones SM, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 2007; 119:199-205.
39. Longo G, Barbi E, Berti I, et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol 2008; 121:343-347.
40. Severino MG, Cortellini G, Bonadonna P, et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 2008; 122:44-48. The use of SLIT is extended in this study to patients experiencing large local reactions to honeybee stings. With clinical efficacy and minimal adverse reactions, the next step will be to study honeybee SLIT for the indicated purpose of treating sting-induced anaphylaxis.
41. Cox L, Li JT, Nelson H, Lockey R. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120:S25-S85. An extensive update to 2003 parameter put out by the Joint Task Force on practice parameters reviewing and offering recommendations on all aspects of specific immunotherapy.
42. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62:317-324. Expert task force presents recommendations for study design, patient selection and outcome measures to use in clinical trials of specific immunotherapy.
43. Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61 ((Supp 82)):1-20.
44. Passalacqua G, Musarra A, Pecora S, et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY Project: evaluation of a novel SLIT formulation during a year). Pediatr Allergy Immunol 2007; 18:58-62. An Italian study of compliance at 3 and 6 months in 71 children on daily SLIT from a unit dose container. By counting containers, compliance was assessed. At 3 months, nine patients had more than 75% compliance and two of them had discontinued.
45. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117:134-140.